TY  - JOUR
AU  - Pérez‐Quintanilla, Damian
AU  - Gómez‐Ruiz, Santiago
AU  - Žižak, Željko
AU  - Sierra, Isabel
AU  - Prashar, Sanjiv
AU  - del Hierro, Isabel
AU  - Fajardo, Mariano
AU  - Juranić, Zorica
AU  - Kaluđerović, Goran N.
PY  - 2009
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/4124
AB  - Dehydroxylated MCM-41 and SBA-15 surfaces were modified by the grafting of two different titanocene complexes ([Ti(Tη5-C5H 4Me)2Cl2] and [Ti(Me2Si(η 5-C5Me4) (η5-C5H 4)}Cl2]) to give new materials, which have been characterized by powder X-ray diffraction, X-ray fluorescence, nitrogen gas sorption, MAS-NMR spectroscopy, thermogravimetry, SEM, and TEM. The toxicity of the resulting materials toward human adenocarcinoma HeLa, human myelogenous leukemia K562, human malignant melanoma Fem-x, and normal immunocompetent cells, such as peripheral blood mononuclear cells PBMC has been studied. Estimation of the number of particles per gram of material led to the calculation of O 50 values for these samples, which is the number of particles required to inhibit normal cell growth by 50%. In addition, M50 values (quantity of material needed to inhibit normal cell growth by 50%) of the studied surfaces is also reported. Nonfunctionalized MCM-41 and SBA-15 did not show notable antiproliferative activity, whereas functionalization of these materials with different titanocene based anticancer drugs led to very promising antitumoral activity. The best Q50 values correspond to titanocene functionalized MCM-41 surfaces (MCM-41/[Ti(η5C5H 4Me)2Cl2] (1) and MCM-41/[TiIMe 2Si(Tf-C5Me4)(Tf-C5H 4)(Cl2] (2)) with Q50 values between 3.8 ± 0.6 x 108 and 24.5 ±3.0 x 108 particles. Titanocene functionalized SBA-15 surfaces (SBA-15/[Ti(η5-C 5H4Me)2Cl2] (3) and SBA-15/[Ti{Me2Si(η5-C5Me 4)(η5C5H4)}Cl2] (4)) gave higher Q50 values, showing lower activity from 73.2 ± 9.9 x 108 to 362±7×l08 particles. The best response of the studied materials in terms of M50 values was observed against Fem-x (309 ± 42 g for 4) and K562 (338±18 g for 2), whereas moderate activities were observed in HeLa cells (from 508±63g of 2 to 912 ± 10g of 1). In addition, the analyzed surfaces presented only marginal activity against unstimulated and stimulated PBMC, showing a slight selectivity on human cancer cells. Comparison of the in vitro cytotoxicity in solution of the titanocene complexes/[Ti(η5-C5H 4Me)2Cl2] (3) and SBA-15/[Ti{Me 2Si(η5-C5Me4) (η5C5H4)}Cl2] (4)) gave higher Q50 va and the corresponding titanocene functionalized materials is also described.
PB  - Wiley
T2  - Chemistry a European Journal
T1  - A New Generation of Anticancer Drugs: Mesoporous Materials Modified with Titanocene Complexes
VL  - 15
IS  - 22
SP  - 5588
EP  - 5597
DO  - 10.1002/chem.200900151
ER  - 

@article{
author = "Pérez‐Quintanilla, Damian and Gómez‐Ruiz, Santiago and Žižak, Željko and Sierra, Isabel and Prashar, Sanjiv and del Hierro, Isabel and Fajardo, Mariano and Juranić, Zorica and Kaluđerović, Goran N.",
year = "2009",
abstract = "Dehydroxylated MCM-41 and SBA-15 surfaces were modified by the grafting of two different titanocene complexes ([Ti(Tη5-C5H 4Me)2Cl2] and [Ti(Me2Si(η 5-C5Me4) (η5-C5H 4)}Cl2]) to give new materials, which have been characterized by powder X-ray diffraction, X-ray fluorescence, nitrogen gas sorption, MAS-NMR spectroscopy, thermogravimetry, SEM, and TEM. The toxicity of the resulting materials toward human adenocarcinoma HeLa, human myelogenous leukemia K562, human malignant melanoma Fem-x, and normal immunocompetent cells, such as peripheral blood mononuclear cells PBMC has been studied. Estimation of the number of particles per gram of material led to the calculation of O 50 values for these samples, which is the number of particles required to inhibit normal cell growth by 50%. In addition, M50 values (quantity of material needed to inhibit normal cell growth by 50%) of the studied surfaces is also reported. Nonfunctionalized MCM-41 and SBA-15 did not show notable antiproliferative activity, whereas functionalization of these materials with different titanocene based anticancer drugs led to very promising antitumoral activity. The best Q50 values correspond to titanocene functionalized MCM-41 surfaces (MCM-41/[Ti(η5C5H 4Me)2Cl2] (1) and MCM-41/[TiIMe 2Si(Tf-C5Me4)(Tf-C5H 4)(Cl2] (2)) with Q50 values between 3.8 ± 0.6 x 108 and 24.5 ±3.0 x 108 particles. Titanocene functionalized SBA-15 surfaces (SBA-15/[Ti(η5-C 5H4Me)2Cl2] (3) and SBA-15/[Ti{Me2Si(η5-C5Me 4)(η5C5H4)}Cl2] (4)) gave higher Q50 values, showing lower activity from 73.2 ± 9.9 x 108 to 362±7×l08 particles. The best response of the studied materials in terms of M50 values was observed against Fem-x (309 ± 42 g for 4) and K562 (338±18 g for 2), whereas moderate activities were observed in HeLa cells (from 508±63g of 2 to 912 ± 10g of 1). In addition, the analyzed surfaces presented only marginal activity against unstimulated and stimulated PBMC, showing a slight selectivity on human cancer cells. Comparison of the in vitro cytotoxicity in solution of the titanocene complexes/[Ti(η5-C5H 4Me)2Cl2] (3) and SBA-15/[Ti{Me 2Si(η5-C5Me4) (η5C5H4)}Cl2] (4)) gave higher Q50 va and the corresponding titanocene functionalized materials is also described.",
publisher = "Wiley",
journal = "Chemistry a European Journal",
title = "A New Generation of Anticancer Drugs: Mesoporous Materials Modified with Titanocene Complexes",
volume = "15",
number = "22",
pages = "5588-5597",
doi = "10.1002/chem.200900151"
}

Pérez‐Quintanilla, D., Gómez‐Ruiz, S., Žižak, Ž., Sierra, I., Prashar, S., del Hierro, I., Fajardo, M., Juranić, Z.,& Kaluđerović, G. N.. (2009). A New Generation of Anticancer Drugs: Mesoporous Materials Modified with Titanocene Complexes. in Chemistry a European Journal
Wiley., 15(22), 5588-5597.
https://doi.org/10.1002/chem.200900151

Pérez‐Quintanilla D, Gómez‐Ruiz S, Žižak Ž, Sierra I, Prashar S, del Hierro I, Fajardo M, Juranić Z, Kaluđerović GN. A New Generation of Anticancer Drugs: Mesoporous Materials Modified with Titanocene Complexes. in Chemistry a European Journal. 2009;15(22):5588-5597.
doi:10.1002/chem.200900151 .

Pérez‐Quintanilla, Damian, Gómez‐Ruiz, Santiago, Žižak, Željko, Sierra, Isabel, Prashar, Sanjiv, del Hierro, Isabel, Fajardo, Mariano, Juranić, Zorica, Kaluđerović, Goran N., "A New Generation of Anticancer Drugs: Mesoporous Materials Modified with Titanocene Complexes" in Chemistry a European Journal, 15, no. 22 (2009):5588-5597,
https://doi.org/10.1002/chem.200900151 . .

TY  - JOUR
AU  - Gomez-Ruiz, Santiago
AU  - Kaluđerović, Goran N.
AU  - Prashar, Sanjiv
AU  - Polo-Ceron, Dorian
AU  - Fajardo, Mariano
AU  - Žižak, Željko
AU  - Sabo, Tibor
AU  - Juranić, Zorica
PY  - 2008
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/4130
AB  - A variety of substituted titanocene and ansa-titanocene complexes have been synthesized and characterized using traditional methods.
The cytotoxic activity of the different titanocene complexes was tested against tumour cell lines human adenocarcinoma HeLa, human
myelogenous leukemia K562, human malignant melanoma Fem-x and normal immunocompetent cells, peripheral blood mononuclear
cells PBMC. Alkenyl substitution, either on the cyclopentadienyl ring or on the silicon-atom ansa-bridge of the titanocene compounds
[Ti{Me2Si(g5-C5Me4)(g5-C5H3{CMe2CH2CH2CH@CH2})}Cl2] (8), [Ti{Me(CH2@CH)Si(g5-C5Me4)(g5-C5H4)}Cl2] (9) and [Ti(g5-
C5H4{CMe2CH2CH2CH@CH2})2Cl2] (12) showed higher cytotoxic activities (IC50 values from 24  } 3 to 151  } 10 lM) relative to complexes
bearing an additional alkenyl-substituted silyl substituent on the silicon bridge [Ti{Me{(CH2@CH)Me2SiCH2CH2}Si(g5-
C5Me4)(g5-C5H4)}Cl2] (10) and [Ti{Me{(CH2@CH)3SiCH2CH2}Si(g5-C5Me4)(g5-C5H4)}Cl2] (11) which causes a dramatic decrease
of the cytotoxicity (IC50 values from 155  } 9 to >200 lM). In addition, the synthesis of the analogous niobocene complex [Nb(g5-
C5H4{CMe2CH2CH2CH=CH2})2Cl2] (13), is described. Structural studies based on DFT calculations of the most active complexes 8,
9 and 12 and the X-ray crystal structure of 13 are reported.
PB  - Elsevier
T2  - Journal of Inorganic Biochemistry
T1  - Cytotoxic studies of substituted titanocene and ansa-titanocene anticancer drugs
VL  - 102
IS  - 8
SP  - 1558
EP  - 1570
DO  - 10.1016/j.jinorgbio.2008.02.001
ER  - 

@article{
author = "Gomez-Ruiz, Santiago and Kaluđerović, Goran N. and Prashar, Sanjiv and Polo-Ceron, Dorian and Fajardo, Mariano and Žižak, Željko and Sabo, Tibor and Juranić, Zorica",
year = "2008",
abstract = "A variety of substituted titanocene and ansa-titanocene complexes have been synthesized and characterized using traditional methods.
The cytotoxic activity of the different titanocene complexes was tested against tumour cell lines human adenocarcinoma HeLa, human
myelogenous leukemia K562, human malignant melanoma Fem-x and normal immunocompetent cells, peripheral blood mononuclear
cells PBMC. Alkenyl substitution, either on the cyclopentadienyl ring or on the silicon-atom ansa-bridge of the titanocene compounds
[Ti{Me2Si(g5-C5Me4)(g5-C5H3{CMe2CH2CH2CH@CH2})}Cl2] (8), [Ti{Me(CH2@CH)Si(g5-C5Me4)(g5-C5H4)}Cl2] (9) and [Ti(g5-
C5H4{CMe2CH2CH2CH@CH2})2Cl2] (12) showed higher cytotoxic activities (IC50 values from 24  } 3 to 151  } 10 lM) relative to complexes
bearing an additional alkenyl-substituted silyl substituent on the silicon bridge [Ti{Me{(CH2@CH)Me2SiCH2CH2}Si(g5-
C5Me4)(g5-C5H4)}Cl2] (10) and [Ti{Me{(CH2@CH)3SiCH2CH2}Si(g5-C5Me4)(g5-C5H4)}Cl2] (11) which causes a dramatic decrease
of the cytotoxicity (IC50 values from 155  } 9 to >200 lM). In addition, the synthesis of the analogous niobocene complex [Nb(g5-
C5H4{CMe2CH2CH2CH=CH2})2Cl2] (13), is described. Structural studies based on DFT calculations of the most active complexes 8,
9 and 12 and the X-ray crystal structure of 13 are reported.",
publisher = "Elsevier",
journal = "Journal of Inorganic Biochemistry",
title = "Cytotoxic studies of substituted titanocene and ansa-titanocene anticancer drugs",
volume = "102",
number = "8",
pages = "1558-1570",
doi = "10.1016/j.jinorgbio.2008.02.001"
}

Gomez-Ruiz, S., Kaluđerović, G. N., Prashar, S., Polo-Ceron, D., Fajardo, M., Žižak, Ž., Sabo, T.,& Juranić, Z.. (2008). Cytotoxic studies of substituted titanocene and ansa-titanocene anticancer drugs. in Journal of Inorganic Biochemistry
Elsevier., 102(8), 1558-1570.
https://doi.org/10.1016/j.jinorgbio.2008.02.001

Gomez-Ruiz S, Kaluđerović GN, Prashar S, Polo-Ceron D, Fajardo M, Žižak Ž, Sabo T, Juranić Z. Cytotoxic studies of substituted titanocene and ansa-titanocene anticancer drugs. in Journal of Inorganic Biochemistry. 2008;102(8):1558-1570.
doi:10.1016/j.jinorgbio.2008.02.001 .

Gomez-Ruiz, Santiago, Kaluđerović, Goran N., Prashar, Sanjiv, Polo-Ceron, Dorian, Fajardo, Mariano, Žižak, Željko, Sabo, Tibor, Juranić, Zorica, "Cytotoxic studies of substituted titanocene and ansa-titanocene anticancer drugs" in Journal of Inorganic Biochemistry, 102, no. 8 (2008):1558-1570,
https://doi.org/10.1016/j.jinorgbio.2008.02.001 . .